Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease
NCT02244216 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2914
Last updated 2014-09-19
Summary
Study to obtain data about changing from the chlorofluorocarbon (CFC) - containing Berotec® 200 µg metered - dose inhaler to the CFC - free Berotec® N 100 µg metered - dose inhaler
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
- DRUG
-
Berotec® N 100 µg Metered-dose Inhaler
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-04-30
- Primary Completion
- 2000-06-30
More Related Trials
-
Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
NCT02238171 ·Status: COMPLETED
-
Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
NCT02233894 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease
NCT02238197 ·Status: COMPLETED
-
Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02233881 ·Status: COMPLETED
-
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease
NCT02231346 ·Status: COMPLETED
-
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
NCT02231320 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis
NCT02233920 ·Status: COMPLETED
-
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
NCT02238158 ·Status: COMPLETED
-
Evaluation of the Respimat Inhaler vs. a HFA MDI Using Berodual in Patients With COPD With Poor MDI Technique.
NCT00267917 ·Status: COMPLETED ·Phase: PHASE4
-
Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease
NCT02176187 ·Status: TERMINATED ·Phase: PHASE3
-
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00153075 ·Status: COMPLETED ·Phase: PHASE4
-
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
NCT02231372 ·Status: COMPLETED
-
Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease
NCT02233907 ·Status: COMPLETED
-
Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT02238184 ·Status: COMPLETED
-
The Asthma Bronchial Challenge Study
NCT03575663 ·Status: COMPLETED
-
Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02236169 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
NCT06297668 ·Status: COMPLETED ·Phase: PHASE1
-
Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT02176200 ·Status: TERMINATED ·Phase: PHASE3
-
Functional Respiratory Imaging Study (FRI)
NCT03268226 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Effect of Formoterol and Beclomethasone Dipropionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01204034 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
NCT04078126 ·Status: COMPLETED ·Phase: PHASE3
-
Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
NCT01176747 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)
NCT02182869 ·Status: TERMINATED ·Phase: PHASE2
-
Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction
NCT01033669 ·Status: COMPLETED
-
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
NCT04663386 ·Status: TERMINATED